Armata Pharmaceuticals (ARMP) Equity Ratio (2016 - 2026)
Quarterly results put Equity Ratio at 4.46 for Q1 2026, down 624.17% from a year ago — trailing twelve months through Mar 2026 was 4.46 (down 624.17% YoY), and the annual figure for FY2025 was 2.84, down 411.8%.
Armata Pharmaceuticals has reported Equity Ratio over the past 14 years, most recently at 4.46 for Q1 2026.
- Equity Ratio reached 4.46 in Q1 2026 per ARMP's latest filing, down from 2.84 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.57 in Q1 2022 and bottomed at 4.46 in Q1 2026.
- Median Equity Ratio over the past 5 years was 0.43 (2024), compared with a mean of 0.58.
- The largest annual shift saw Equity Ratio grew 3.42% in 2022 before it plummeted 624.17% in 2026.
- Over 5 years, Equity Ratio stood at 0.38 in 2022, then crashed by 186.59% to 0.33 in 2023, then tumbled by 70.42% to 0.56 in 2024, then tumbled by 411.8% to 2.84 in 2025, then plummeted by 57.0% to 4.46 in 2026.
- Business Quant data shows Equity Ratio for ARMP at 4.46 in Q1 2026, 2.84 in Q4 2025, and 1.07 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 0.73 |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.77 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 0.21 |
| 10 | Armata Pharmaceuticals | 301.92 Mn | 297.17 Mn | - | -4.46 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.46 |
| Dec 31, 2025 | -2.84 |
| Sep 30, 2025 | -1.07 |
| Jun 30, 2025 | -0.86 |
| Mar 31, 2025 | -0.62 |
| Dec 31, 2024 | -0.56 |
| Sep 30, 2024 | -0.52 |
| Jun 30, 2024 | -0.43 |
| Mar 31, 2024 | -0.47 |
| Dec 31, 2023 | -0.33 |
| Sep 30, 2023 | -0.11 |
| Jun 30, 2023 | 0.19 |
| Mar 31, 2023 | 0.21 |
| Dec 31, 2022 | 0.38 |
| Sep 30, 2022 | 0.49 |
| Jun 30, 2022 | 0.53 |
| Mar 31, 2022 | 0.57 |
| Dec 31, 2021 | 0.36 |
| Sep 30, 2021 | 0.56 |
| Jun 30, 2021 | 0.59 |
| Mar 31, 2021 | 0.64 |
| Dec 31, 2020 | 0.48 |
| Sep 30, 2020 | 0.54 |
| Jun 30, 2020 | 0.60 |
| Mar 31, 2020 | 0.76 |
| Dec 31, 2019 | 0.57 |
| Sep 30, 2019 | 0.62 |
| Jun 30, 2019 | 0.65 |
| Mar 31, 2019 | 0.41 |
| Dec 31, 2018 | 0.53 |
| Sep 30, 2018 | 0.83 |
| Jun 30, 2018 | 0.99 |
| Mar 31, 2018 | 1.02 |
| Dec 31, 2017 | 2.19 |
| Sep 30, 2017 | 0.71 |
| Jun 30, 2017 | 0.65 |
| Mar 31, 2017 | 0.46 |
| Dec 31, 2016 | 0.54 |
| Sep 30, 2016 | 0.70 |
| Jun 30, 2016 | 0.73 |